⌕
Sanofi · SNY · Nasdaq
Tenet 34 · Weak
Compare
$48.39+0.04%At closeTenet 34 · Weak
$48.39+0.02 (+0.04%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD
$48.37−0.02 (−0.04%)
After hours: Nov 16, 2026, 6:06 PM ET

Sanofi (SNY) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

The percentage on each card is SNY's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

● GlobeNewsWireNov 3, 2026 · 16:01 ET
Nurix Therapeutics Announces Sanofi's Decision to Discontinue Development of STAT6 Degrader SAR448272

BRISBANE, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on targeted protein degradation medicines, today announced that Sanofi notif…

SNY 0.0% todayRead at source ↗
● Zacks Investment ResearchNov 3, 2026 · 12:01 ET
Recursion's Q3 Earnings Beat Estimates on Sanofi Milestone Revenues

RXRX Q3 revenues surge 258.5%, beating estimates as a $10 million Sanofi milestone payment boosts results and advances its drug pipeline.…

SNY 0.0% todayRead at source ↗
● MarketBeatOct 30, 2026 · 12:17 ET
Sanofi Q3 Earnings Call Highlights

Sanofi NASDAQ: SNY reported third-quarter 2026 sales growth of 14.3% at constant exchange rates, supported by continued demand for Dupixent, recently launched medicines and growth in rare diseases. The company also raise…

SNY 0.0% todayRead at source ↗
● BenzingaOct 30, 2026 · 11:09 ET
Dupixent Is Still Booming. Sanofi's CEO Is Already Planning for Life Without It

Sanofi SA (NASDAQ:SNY) on Friday reported third-quarter sales of $16.623 billion (14.444 billion euros), beating the consensus of $15.23 billion. Sales increased 16.2% year over year, up 14.3% in constant currency.…

SNY 0.0% todayRead at source ↗
● 24/7 Wall StreetOct 30, 2026 · 11:06 ET
Regeneron Surges 12% as Sanofi Dupixent Windfall and Eylea HD Power Earnings Beat; Moderna Slides 2%, Merck Edges Higher, Pfizer Ticks Up

A strong third quarter has made Regeneron Pharmaceuticals (NASDAQ:REGN | REGN Price Prediction) a standout healthcare gainer on a day when tech stocks are selling off. In morning trading, Regeneron stock has climbed to $…

SNY 0.0% todayRead at source ↗
● Zacks Investment ResearchOct 30, 2026 · 11:06 ET
Sanofi Q3 Earnings & Sales Beat, 2026 View Up, Shares Rise

SNY beats Q3 earnings and sales estimates as Dupixent drives growth and the company raises its 2026 outlook for sales and business EPS.…

SNY 0.0% todayRead at source ↗
● WSJOct 30, 2026 · 02:54 ET
Sanofi CEO Sets Sights on Deals to Drive Turnaround

The French drugmaker is moving to fill its medicine pipeline to prepare for the looming patent expiration of its bestselling product, Dupixent.…

SNY 0.0% todayRead at source ↗
● 24/7 Wall StreetOct 26, 2026 · 09:39 ET
Regeneron's Billion-Dollar Catalyst Flying Under Wall Street's Radar Ahead of Oct. 30 Earnings

Regeneron (NASDAQ:REGN | REGN Price Prediction) reports third-quarter results on Oct. 30. Regeneron books its full share of Dupixent profits from Sanofi (NASDAQ:SNY) for the first time this quarter.…

SNY 0.0% todayRead at source ↗
● Seeking AlphaOct 26, 2026 · 09:30 ET
Sanofi: An Alluring And Balanced Mix Of Yield And Growth

Sanofi has increased its dividend for 31 consecutive years. It's only because this is not an American company in the S&P 500 that it's not a dividend aristocrat. Sanofi increased its revenue from €34.7 billion in FY 2016…

SNY 0.0% todayRead at source ↗
● Seeking AlphaOct 20, 2026 · 15:26 ET
Sanofi: Why The Market Seems To Be Overpricing Pipeline Risk

Sanofi is deeply undervalued, trading at 8.4x P/E despite AA rating, robust balance sheet, and a 5.8% dividend yield. I see SNY pipeline risks as overstated; Dupixent's expansion and multiple smaller launches provide sol…

SNY 0.0% todayRead at source ↗
● Business WireOct 20, 2026 · 09:10 ET
ScionxBio Announces Collaboration to Develop Long-Acting xRNA Therapeutics

CAMBRIDGE, England--(BUSINESS WIRE)--ScionxBio (the “company”, operating as a brand identity of Eleven Therapeutics Ltd. following a horizontal split) a privately held, preclinical-stage biotechnology company pioneering …

SNY 0.0% todayRead at source ↗
● GlobeNewsWireOct 19, 2026 · 08:04 ET
Enable Injections Announces Approval in Japan for CirCLIQ® Injector based on enFuse® On-Body Delivery System

Sanofi's CirCLIQ® Injector, developed using enFuse technology, has been approved to administer Sarclisa subcutaneous formulation, in combination with approved standard-of-care regimens, for patients with multiple myeloma…

SNY 0.0% todayRead at source ↗
● GlobeNewsWireOct 19, 2026 · 06:30 ET
Press Release: Sanofi breaks ground on new state-of-the-art insulin manufacturing facility in Germany

Sanofi breaks ground on new state-of-the-art insulin manufacturing facility in Germany Paris and Frankfurt, October 19, 2 026. Sanofi today broke ground on a new state-of-the-art insulin manufacturing facility at its Bio…

SNY 0.0% todayRead at source ↗
● GlobeNewsWireOct 15, 2026 · 08:45 ET
Recursion Announces Sanofi Options Potential First-in-Class Immunology Development Candidate from Their Collaboration

Potential first-in-class dual targeting inhibitor oral small molecule to enter Sanofi's development pipeline, with phase 1 clinical study currently planned to begin in 2027 Potential first-in-class dual targeting inhibit…

SNY 0.0% todayRead at source ↗
● Zacks Investment ResearchOct 14, 2026 · 13:11 ET
Which Pharma Stock Looks More Attractive: Sanofi or AbbVie?

Sanofi's upgraded 2026 outlook, Dupixent growth and attractive valuation give it an edge over AbbVie, despite pipeline setbacks and vaccine sales challenges.…

SNY 0.0% todayRead at source ↗
● WSJOct 14, 2026 · 04:26 ET
EU Accepts Sanofi's Concessions to Settle Antitrust Probe Over Vaccine Marketing

Sanofi's offer to rectify the potential effects of its past messages on a rival flu shot awould address concerns, the bloc's executive arm said.…

SNY 0.0% todayRead at source ↗
● Defense WorldOct 11, 2026 · 08:15 ET
Head to Head Review: Sanofi (NASDAQ:SNY) vs. Scilex (NASDAQ:SCLX)

Sanofi (NASDAQ: SNY - Get Free Report) and Scilex (NASDAQ: SCLX - Get Free Report) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their analy…

SNY 0.0% todayRead at source ↗
● GlobeNewsWireOct 6, 2026 · 01:30 ET
Press Release : Availability of the aide-mémoire for Q3 2026 results

Availability of the aide-mémoire for Q3 2026 results Paris, France – October 6, 2026. Sanofi announced today the availability of the aide-mémoire for Q3 2026 results on the "Investors" page of sanofi.com: Third quarter 2…

SNY 0.0% todayRead at source ↗
● 24/7 Wall StreetOct 5, 2026 · 15:02 ET
Novavax Soars 22% as Sanofi Carries Nuvaxovid Into Vaccination Season; Moderna Climbs 8%, BioNTech Ticks Up

Sanofi is carrying the Nuvaxovid COVID-19 shot into the fall vaccination season, and buyers are rewarding shares of licensor Novavax (NASDAQ:NVAX) far more heavily than the rest of biotech. Novavax stock has rose 17% dur…

SNY 0.0% todayRead at source ↗
● Business WireOct 5, 2026 · 13:59 ET
As First Dupixent MDL Hearing Opens, Weitz & Luxenberg Points to Sanofi's Own Words on a Cancer That Hides Behind Eczema

NEW YORK--(BUSINESS WIRE)--Weitz & Luxenberg, which represents more people in the Dupixent litigation than any other firm, appeared this past Friday at the first hearing in the federal multidistrict litigation over alleg…

SNY 0.0% todayRead at source ↗
● PRNewsWireOct 2, 2026 · 11:57 ETCOMPANY'S OWN WORDS
Sanofi and 2026 NBA Champion Karl-Anthony Towns team up to raise awareness of COVID-19 vaccination with NUVAXOVID®

The six-time NBA All-Star, three-time All-NBA selection, 2016 NBA Rookie of the Year, and 2026 NBA Champion Karl-Anthony Towns brings his personal experience with COVID-19 to encourage eligible people, especially those a…

SNY 0.0% todayRead at source ↗
● Zacks Investment ResearchOct 2, 2026 · 10:46 ET
Sanofi, Regeneron Expand Immunology Alliance With New Antibodies

SNY and REGN expand their longstanding alliance to four new antibodies targeting type II inflammation, with billions in potential payments.…

SNY 0.0% todayRead at source ↗
● Seeking AlphaOct 1, 2026 · 13:29 ET
Regeneron And Sanofi Announce A Win-Win Collaboration Expansion

Regeneron and Sanofi announced a strategic expansion of their antibody collaboration, targeting IL-4/IL-13 pathways for next-generation inflammation and immunology therapies. The deal grants REGN $1B upfront and up to $7…

SNY 0.0% todayRead at source ↗
● GlobeNewsWireOct 1, 2026 · 01:00 ET
Press Release: Sanofi and Regeneron expand global Alliance with multiple next-generation, long-acting immunology antibodies

Sanofi and Regeneron expand global Alliance with multiple nex t-generation, long-acting immunology antibodies REGN20423, a clinical-stage long-acting IL-13 monoclonal antibody invented and developed by Regeneron, is adde…

SNY 0.0% todayRead at source ↗
● GlobeNewsWireOct 1, 2026 · 01:00 ET
Regeneron and Sanofi Expand Global Alliance with Multiple Next-Generation, Long-Acting Immunology Antibodies

REGN20423, a clinical-stage long-acting IL-13 monoclonal antibody invented and developed by Regeneron, is added to the alliance, along with a long-acting IL-4xIL-13 bispecific and two other long-acting preclinical antibo…

SNY 0.0% todayRead at source ↗

Kept in their own lane. A press release is the company talking, not reporting.

No upcoming events in the feeds.

Article counts from the last market-wide feed page, across every symbol we track and not just SNY · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.